- Home
- ELDN vs NPWR Comparison
ELDN vs NPWR Comparison
Compare ELDN & NPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- NPWR
- Stock Information
- Founded
- ELDN 2004
- NPWR 2010
- Country
- ELDN United States
- NPWR United States
- Employees
- ELDN N/A
- NPWR N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- NPWR Industrial Machinery/Components
- Sector
- ELDN Health Care
- NPWR Energy
- Exchange
- ELDN Nasdaq
- NPWR Nasdaq
- Market Cap
- ELDN 202.4M
- NPWR 171.3M
- IPO Year
- ELDN N/A
- NPWR N/A
- Fundamental
- Price
- ELDN $2.73
- NPWR $3.56
- Analyst Decision
- ELDN Strong Buy
- NPWR Buy
- Analyst Count
- ELDN 2
- NPWR 2
- Target Price
- ELDN $12.50
- NPWR $4.00
- AVG Volume (30 Days)
- ELDN 998.5K
- NPWR 1.3M
- Earning Date
- ELDN 11-11-2025
- NPWR 11-10-2025
- Dividend Yield
- ELDN N/A
- NPWR N/A
- EPS Growth
- ELDN N/A
- NPWR N/A
- EPS
- ELDN 0.21
- NPWR N/A
- Revenue
- ELDN N/A
- NPWR $12,000.00
- Revenue This Year
- ELDN N/A
- NPWR N/A
- Revenue Next Year
- ELDN N/A
- NPWR N/A
- P/E Ratio
- ELDN $12.80
- NPWR N/A
- Revenue Growth
- ELDN N/A
- NPWR N/A
- 52 Week Low
- ELDN $2.32
- NPWR $1.48
- 52 Week High
- ELDN $5.54
- NPWR $14.28
- Technical
- Relative Strength Index (RSI)
- ELDN 54.22
- NPWR 68.86
- Support Level
- ELDN $2.48
- NPWR $2.94
- Resistance Level
- ELDN $2.71
- NPWR $3.87
- Average True Range (ATR)
- ELDN 0.17
- NPWR 0.32
- MACD
- ELDN 0.04
- NPWR 0.10
- Stochastic Oscillator
- ELDN 60.95
- NPWR 81.25
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.